Variant rs9929218 Linked with Prognosis of Patients with CRC
the Cancer Therapy Advisor take:
Patients with stage 4 colorectal cancer (CRC) who have the variant rs9929218 at 16q22 (intron 2 of CDH1, encoding E-cadherin) are at an increased risk for worse survival and poor response to chemotherapy, according to an article published online in the journal Clinical Cancer Research.
Initially, the authors analyzed 20 single-nucleotide polymorphism (SNPs) associated with risk of CRC from 14 genome-wide loci and how they affected the prognosis of 2,083 patients with CRC.
Secondly, three SNPs were analyzed from an independent group of 5,552 patients with advanced stage CRC.
Results showed three variants in the training phase were associated with patient survival. However, only one variant (rs9929218) had a significant association in the validation phase.
Patients who were homozygous for the minor allele, especially those with stage 4 cancer (P=2.7 x 10-5), were observed to have worse survival (training phase HR, 1.43; 95% CI: 1.20, 1.71; P=5.8 × 10−5; validation phase; HR, 1.18; 95% CI: 1.01, 1.37; P=3.2 × 10−2; combined HR, 1.28; 95% CI: 1.14, 1.43; P=2.2 × 10−5).
Furthermore, a significant correlation was observed between the variant rs9929218 and a negative response to chemotherapy (P=3.9 x 10-4).
The study suggests that these findings provide a mechanism underlying rs9929218’s potential in making a patient prognosis.
Patients with colorectal cancer who have the variant rs9929218 at 16q22 are at an increased risk for worse survival.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- CTC Screening May Be Effective Method for Preventing Colorectal Cancer
- Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors
- Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC
- Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC
- Alcohol Consumption and Cancer